可孚醫療(301087.SZ):新型冠狀病毒抗原自測試劑盒等產品獲得歐盟CE認證
格隆匯5月19日丨可孚醫療(301087.SZ)公佈,近日,公司新型冠狀病毒抗原自測試劑盒等產品獲得歐盟CE認證,可在歐盟國家和認可歐盟CE認證的國家銷售。此外,公司收到湖南省藥品監督管理局頒發的多項醫療器械變更註冊文件。具體情況如下:
歐盟CE認證情況

國內醫療器械註冊證變更情況


上述產品所獲得的歐盟CE認證和取得的醫療器械註冊變更文件,將進一步完善公司在歐盟市場及國內市場的產品結構,將對公司未來發展具有積極影響。公司未來會積極推動相關產品在歐盟市場及國內市場的銷售,為廣大股東創造更大的價值。
上述醫療器械註冊證涉及的相關產品上市後實際銷售情況取決於未來市場的推廣效果,目前尚無法預測其對公司未來業績的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.